Literature DB >> 23913866

Kinetic differences in the induction of interferon stimulated genes by interferon-α and interleukin 28B are altered by infection with hepatitis C virus.

Nikolaus Jilg1, Wenyu Lin, Jian Hong, Esperance A Schaefer, David Wolski, James Meixong, Kaku Goto, Cynthia Brisac, Pattranuch Chusri, Dahlene N Fusco, Stephane Chevaliez, Jay Luther, Kattareeya Kumthip, Thomas J Urban, Lee F Peng, Georg M Lauer, Raymond T Chung.   

Abstract

UNLABELLED: Several genome-wide association studies (GWAS) have identified a genetic polymorphism associated with the gene locus for interleukin 28B (IL28B), a type III interferon (IFN), as a major predictor of clinical outcome in hepatitis C. Antiviral effects of the type III IFN family have previously been shown against several viruses, including hepatitis C virus (HCV), and resemble the function of type I IFN including utilization of the intracellular Janus kinase signal transducer and activator of transcription (JAK-STAT) pathway. Effects unique to IL28B that would distinguish it from IFN-α are not well defined. By analyzing the transcriptomes of primary human hepatocytes (PHH) treated with IFN-α or IL28B, we sought to identify functional differences between IFN-α and IL28B to better understand the roles of these cytokines in the innate immune response. Although our data did not reveal distinct gene signatures, we detected striking kinetic differences between IFN-α and IL28B stimulation for interferon stimulated genes (ISGs). While gene induction was rapid and peaked at 8 hours of stimulation with IFN-α in PHH, IL28B produced a slower, but more sustained increase in gene expression. We confirmed these findings in the human hepatoma cell line Huh7.5.1. Interestingly, in HCV-infected cells the rapid response after stimulation with IFN-α was blunted, and the induction pattern resembled that caused by IL28B.
CONCLUSION: The kinetics of gene induction are fundamentally different for stimulations with either IFN-α or IL28B in hepatocytes, suggesting distinct roles of these cytokines within the immune response. Furthermore, the observed differences are substantially altered by infection with HCV.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23913866      PMCID: PMC3909557          DOI: 10.1002/hep.26653

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  37 in total

1.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

2.  Use of human hepatocytes to study P450 gene induction.

Authors:  S C Strom; L A Pisarov; K Dorko; M T Thompson; J D Schuetz; E G Schuetz
Journal:  Methods Enzymol       Date:  1996       Impact factor: 1.600

3.  IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex.

Authors:  Sergei V Kotenko; Grant Gallagher; Vitaliy V Baurin; Anita Lewis-Antes; Meiling Shen; Nital K Shah; Jerome A Langer; Faruk Sheikh; Harold Dickensheets; Raymond P Donnelly
Journal:  Nat Immunol       Date:  2002-12-16       Impact factor: 25.606

4.  HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons.

Authors:  Emmanuel Thomas; Veronica D Gonzalez; Qisheng Li; Ankit A Modi; Weiping Chen; Mazen Noureddin; Yaron Rotman; T Jake Liang
Journal:  Gastroenterology       Date:  2012-01-13       Impact factor: 22.682

5.  Interferon-alpha activates multiple STAT signals and down-regulates c-Met in primary human hepatocytes.

Authors:  Svetlana Radaeva; Barbara Jaruga; Feng Hong; Won-Ho Kim; Saijun Fan; Hongbo Cai; Stephen Strom; Youhua Liu; Osama El-Assal; Bin Gao
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

6.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus.

Authors:  Ludmila Prokunina-Olsson; Brian Muchmore; Wei Tang; Ruth M Pfeiffer; Heiyoung Park; Harold Dickensheets; Dianna Hergott; Patricia Porter-Gill; Adam Mumy; Indu Kohaar; Sabrina Chen; Nathan Brand; McAnthony Tarway; Luyang Liu; Faruk Sheikh; Jacquie Astemborski; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Timothy R Morgan; David L Thomas; Barbara Rehermann; Raymond P Donnelly; Thomas R O'Brien
Journal:  Nat Genet       Date:  2013-01-06       Impact factor: 38.330

7.  Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

Authors:  J Tilman Gerlach; Helmut M Diepolder; Reinhart Zachoval; Norbert H Gruener; Maria-Christina Jung; Axel Ulsenheimer; Winfried W Schraut; C Albrecht Schirren; M Waechtler; M Backmund; Gerd R Pape
Journal:  Gastroenterology       Date:  2003-07       Impact factor: 22.682

8.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

9.  Hepatitis C virus NS5A disrupts STAT1 phosphorylation and suppresses type I interferon signaling.

Authors:  Kattareeya Kumthip; Pattranuch Chusri; Nikolaus Jilg; Lei Zhao; Dahlene N Fusco; Hong Zhao; Kaku Goto; Du Cheng; Esperance A Schaefer; Leiliang Zhang; Chansom Pantip; Satawat Thongsawat; Amornrat O'Brien; Lee F Peng; Niwat Maneekarn; Raymond T Chung; Wenyu Lin
Journal:  J Virol       Date:  2012-06-06       Impact factor: 5.103

10.  IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction.

Authors:  Stéphanie Bibert; Thierry Roger; Thierry Calandra; Murielle Bochud; Andreas Cerny; Nasser Semmo; François H T Duong; Tilman Gerlach; Raffaele Malinverni; Darius Moradpour; Francesco Negro; Beat Müllhaupt; Pierre-Yves Bochud
Journal:  J Exp Med       Date:  2013-05-27       Impact factor: 14.307

View more
  56 in total

1.  EFTUD2 Is a Novel Innate Immune Regulator Restricting Hepatitis C Virus Infection through the RIG-I/MDA5 Pathway.

Authors:  Chuanlong Zhu; Fei Xiao; Jian Hong; Kun Wang; Xiao Liu; Dachuan Cai; Dahlene N Fusco; Lei Zhao; Soung Won Jeong; Cynthia Brisac; Pattranuch Chusri; Esperance A Schaefer; Hong Zhao; Lee F Peng; Wenyu Lin; Raymond T Chung
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

2.  Respiratory syncytial virus infection induces a subset of types I and III interferons in human dendritic cells.

Authors:  Philippa Hillyer; Viraj P Mane; Aaron Chen; Maria B Dos Santos; Lynnsie M Schramm; Rachel E Shepard; Cindy Luongo; Cyril Le Nouën; Lei Huang; Lihan Yan; Ursula J Buchholz; Ronald G Jubin; Peter L Collins; Ronald L Rabin
Journal:  Virology       Date:  2017-01-31       Impact factor: 3.616

Review 3.  Contribution of type III interferons to antiviral immunity: location, location, location.

Authors:  Sergei V Kotenko; Joan E Durbin
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

4.  Disruption of Type III Interferon (IFN) Genes Ifnl2 and Ifnl3 Recapitulates Loss of the Type III IFN Receptor in the Mucosal Antiviral Response.

Authors:  Stefan T Peterson; Elizabeth A Kennedy; Pamela H Brigleb; Gwen M Taylor; Kelly Urbanek; Traci L Bricker; Sanghyun Lee; Haina Shin; Terence S Dermody; Adrianus C M Boon; Megan T Baldridge
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

5.  A Long Noncoding RNA Regulates Hepatitis C Virus Infection Through Interferon Alpha-Inducible Protein 6.

Authors:  Xiao Liu; Xiaoqiong Duan; Jacinta A Holmes; Wenting Li; Sae Hwan Lee; Zeng Tu; Chuanlong Zhu; Shadi Salloum; Anna Lidofsky; Esperance A Schaefer; Dachuan Cai; Shilin Li; Haoju Wang; Yongfu Huang; Yongju Zhao; Ming-Lung Yu; Zhiwen Xu; Limin Chen; Jian Hong; Wenyu Lin; Raymond T Chung
Journal:  Hepatology       Date:  2019-02-13       Impact factor: 17.425

6.  Comprehensive Proteomics Identification of IFN-λ3-regulated Antiviral Proteins in HBV-transfected Cells.

Authors:  Jiradej Makjaroen; Poorichaya Somparn; Kenneth Hodge; Witthaya Poomipak; Nattiya Hirankarn; Trairak Pisitkun
Journal:  Mol Cell Proteomics       Date:  2018-08-10       Impact factor: 5.911

7.  Immune Cell Profiling of IFN-λ Response Shows pDCs Express Highest Level of IFN-λR1 and Are Directly Responsive via the JAK-STAT Pathway.

Authors:  Aoife Kelly; Mark W Robinson; Gerard Roche; Christine A Biron; Cliona O'Farrelly; Elizabeth J Ryan
Journal:  J Interferon Cytokine Res       Date:  2016-09-12       Impact factor: 2.607

8.  Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness.

Authors:  Timothy Sheahan; Naoko Imanaka; Svetlana Marukian; Marcus Dorner; Peng Liu; Alexander Ploss; Charles M Rice
Journal:  Cell Host Microbe       Date:  2014-02-12       Impact factor: 21.023

9.  The spliceosome factor SART1 exerts its anti-HCV action through mRNA splicing.

Authors:  Wenyu Lin; Chuanlong Zhu; Jian Hong; Lei Zhao; Nikolaus Jilg; Dahlene N Fusco; Esperance A Schaefer; Cynthia Brisac; Xiao Liu; Lee F Peng; Qikai Xu; Raymond T Chung
Journal:  J Hepatol       Date:  2014-12-03       Impact factor: 25.083

10.  SOCS1 is an inducible negative regulator of interferon λ (IFN-λ)-induced gene expression in vivo.

Authors:  Tanja Blumer; Mairene Coto-Llerena; Francois H T Duong; Markus H Heim
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.